Sally Beauty misses top-line estimates; initiates Q2 and reaffirms FY25 outlook Sally Beauty misses top-line estimates; initiates Q2 and reaffirms FY25 outlook Post ContentsbhRead More You might also be interested in reading Anixa Biosciences files $200M mixed securities shelf. February 13, 2025 In Mainstream ← Previous post Next post →